Predicting the Efficacy of an Oral Paclitaxel Formulation (DHP107) Through Modeling and Simulation

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

Neil Desai, Vuong Trieu, Zhiwen Yao et al. · Clinical Cancer Research · 2006 · 1.2K citations

Medicine, Oncology, Pharmacology +14

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

Andrew D. Seidman, Donald A. Berry, Constance Cirrincione et al. · Journal of Clinical Oncology · 2008 · 604 citations · Full text

Medicine, Oncology, Pharmacology +17

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

Luca Gianni, Christine M. Kearns, Antonio Giani et al. · Journal of Clinical Oncology · 1995 · 562 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

Lena E. Friberg, Anja Henningsson, Hugo Maas et al. · Journal of Clinical Oncology · 2002 · 528 citations

Medicine, Oncology, Pharmacology +17

Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines

J. Liebmann, J A Cook, Claudia A. Lipschultz et al. · British Journal of Cancer · 1993 · 424 citations · Full text

Medicine, Oncology, Pharmacology +14